Free Newsletter
Analysts call Gilead a takeover target
Will Gilead Sciences continue to stand alone, or will it fall prey to buyout like its neighbors Chiron and Genentech? The company is dominant in the HIV market and is also exploring hear and lung disease treatments. Report
More stories about Gilead Sciences
Comments
By Anonymous | Posted 3:26pm | September 3, 2008
Rumors are surfacing about a possible buyout. We may hear something real soon.
By Dr. James | Posted 3:33pm | September 3, 2008
Gilead would be a nice synergy for
many sources out there.
By Anonymous | Posted 1:26pm | November 4, 2008
GILD is ripe for a takeover. I estimate that the price should be in the range of $55 to $60.
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: